Chengdu Olymvax Stock Hits Day Low Amid Price Pressure at CNY 25.68

Chengdu Olymvax Biopharmaceuticals, Inc. experienced significant volatility on July 20, 2026, with the stock declining by 14.37% and reaching an intraday low of CNY 25.68. This performance stands in contrast to the China Shanghai Composite, which saw a modest increase of 0.85% on the same day. Over the past week, Chengdu Olymvax has faced a steep decline of 27.06%, while its performance over the past month mirrors this trend, also down 27.06%. However, the company has shown resilience over the past year, achieving a 20.5% increase, significantly outperforming the China Shanghai Composite's 7.41% gain. Financial metrics indicate a robust market position, with a market capitalization of CNY 13,893 million and a notable return on equity of 6.03%. The company has reported a growth in net sales of 25.38% and has maintained a high interest coverage ratio of 1,289.5. Despite the recent downturn, Chengdu Olymvax has demonstrated strong long-term performance, generating 103.83% returns over the last year and outperforming the composite index over multiple time frames.